QCG
NVO

Quadrant Capital Group’s Novo Nordisk NVO Stock Holding History

Quadrant Capital Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.22M Sell
60,354
-34,329
-36% -$1.63M 0.07% 240
2025
Q4 		$4.82M Buy
94,683
+10,341
+12% +$529K 0.15% 98
2025
Q3 		$4.68M Sell
84,342
-36,116
-30% -$2.11M 0.15% 90
2025
Q2 		$8.31M Buy
120,458
+12,641
+12% +$860K 0.3% 43
2025
Q1 		$7.49M Buy
107,817
+72,424
+205% +$5.98M 0.28% 42
2024
Q4 		$3.04M Sell
35,393
-2,806
-7% -$303K 0.21% 54
2024
Q3 		$4.55M Buy
38,199
+1,004
+3% +$134K 0.32% 41
2024
Q2 		$5.31M Buy
37,195
+1,150
+3% +$152K 0.39% 36
2024
Q1 		$4.63M Buy
36,045
+1,009
+3% +$120K 0.37% 38
2023
Q4 		$3.62M Buy
35,036
+2,347
+7% +$232K 0.31% 45
2023
Q3 		$2.97M Buy
32,689
+2,877
+10% +$253K 0.3% 47
2023
Q2 		$2.41M Sell
29,812
-458
-2% -$37.4K 0.24% 58
2023
Q1 		$2.41M Buy
30,270
+2,220
+8% +$157K 0.25% 60
2022
Q4 		$1.9M Buy
28,050
+2,862
+11% +$168K 0.22% 68
2022
Q3 		$1.25M Buy
25,188
+414
+2% +$22.2K 0.17% 88
2022
Q2 		$1.38M Buy
24,774
+1,970
+9% +$109K 0.19% 81
2022
Q1 		$1.27M Buy
22,804
+1,688
+8% +$86.6K 0.15% 89
2021
Q4 		$1.18M Buy
21,116
+2,148
+11% +$116K 0.14% 106
2021
Q3 		$911K Buy
18,968
+530
+3% +$25.6K 0.13% 120
2021
Q2 		$772K Buy
18,438
+1,092
+6% +$42.3K 0.11% 134
2021
Q1 		$585K Buy
17,346
+2,226
+15% +$79.3K 0.09% 155
2020
Q4 		$528K Buy
15,120
+1,204
+9% +$41.6K 0.1% 142
2020
Q3 		$483K Buy
13,916
+2,664
+24% +$88.8K 0.11% 131
2020
Q2 		$368K Sell
11,252
-40,214
-78% -$1.28M 0.08% 170
2020
Q1 		$1.55M Buy
51,466
+954
+2% +$28.4K 0.26% 73
2019
Q4 		$1.44M Buy
50,512
+11,012
+28% +$305K 0.17% 96
2019
Q3 		$1.01M Buy
39,500
+4,744
+14% +$120K 0.15% 110
2019
Q2 		$874K Buy
34,756
+780
+2% +$19.3K 0.14% 117
2019
Q1 		$874K Buy
33,976
+9,362
+38% +$230K 0.15% 110
2018
Q4 		$551K Buy
24,614
+14,198
+136% +$315K 0.15% 115
2018
Q3 		$231K Sell
10,416
-110
-1% -$2.68K 0.07% 205
2018
Q2 		$229K Buy
10,526
+232
+2% +$5.51K 0.08% 210
2018
Q1 		$243K Hold
10,294
– – 0.09% 194
2017
Q4 		$263K Buy
10,294
+208
+2% +$5.29K 0.1% 168
2017
Q3 		$231K Buy
10,086
+958
+10% +$21.6K 0.1% 178
2017
Q2 		$175K Buy
9,128
+4,172
+84% +$84.2K 0.08% 208
2017
Q1 		$77K Buy
4,956
+234
+5% +$4.08K 0.03% 419
2016
Q4 		$74K Buy
4,722
+3,168
+204% +$57.4K 0.04% 329
2016
Q3 		$26K Sell
1,554
-1,556
-50% -$38.6K 0.02% 658
2016
Q2 		$78K Buy
3,110
+88
+3% +$2.41K 0.05% 283
2016
Q1 		$76K Sell
3,022
-1,794
-37% -$48.1K 0.05% 283
2015
Q4 		$135K Sell
4,816
-1,422
-23% -$39.4K 0.09% 196
2015
Q3 		$166K Buy
6,238
+690
+12% +$19.5K 0.11% 149
2015
Q2 		$149K Buy
+5,548
New +$156K 0.09% 179

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Quadrant Capital Group's NVO Position: Q1 2026 in Review

Quadrant Capital Group reduced its Novo Nordisk (NVO) stake by 36% in Q1 2026, selling an estimated $1.63M and leaving 60,354 shares worth $2.22M. The position accounts for 0.07% of the portfolio, ranked #240.

Quadrant Capital Group first reported a position in NVO in Q2 2015 and has held it in 44 quarters since. The position peaked at $8.31M in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Quadrant Capital Group held 60,354 shares of Novo Nordisk worth $2.22M as of Q1 2026.
  • Quadrant Capital Group sold 34,329 Novo Nordisk shares in Q1 2026, an estimated $1.63M.
  • Novo Nordisk made up 0.07% of Quadrant Capital Group's portfolio in Q1 2026, its #240 holding.
  • Quadrant Capital Group first reported a position in Novo Nordisk in Q2 2015 and has held it in 44 quarters since.
  • Quadrant Capital Group's Novo Nordisk position peaked at $8.31M in Q2 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.